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Two novel mutations in the tmprss6 gene associated with
iron-refractory iron-deficiency anaemia (irida) and partial
expression in the heterozygous form
Iron-refractory iron-deficiency anaemia (IRIDA, Online
Mendelian Inheritance in Man number 206200) is an autoso-
mal recessive genetic disorder characterized by iron defi-
ciency anaemia unresponsive to oral iron treatment but
partially responsive to parenteral iron therapy (Finberg,
2009). IRIDA is due to mutations in the TMPRSS6 gene,
which encodes the serine-protease matriptase 2 (Finberg
et al, 2008), an inhibitor of the iron-related hormone, hepci-
din. Several mutations in the TMPRSS6 gene have been char-
acterized in IRIDA families of different ethnic origins. Recent
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findings on Tmprss6-haploinsufficient mice support the
hypothesis that susceptibility to iron deficiency may be
increased by the presence of TMPRSS6 mutations even in the
heterozygous state (Nai et al, 2010). Here we present two
new TMPRSS6 variants that were associated, in the hetero-
zygous form, with manifest IRIDA in two un-related
families.
In the Italian Family 1, the proband was a 9-year-old girl
with microcytic anaemia, low serum iron and normal ferritin
(Fig 1A, C). She had no response to iron oral therapy but
she responded to i.v. iron therapy, reaching haemoglobin val-
ues stably higher than 110 g/l with ferritin values around
440 pmol/l. The molecular study of family members revealed
the absence of HBA1/HBA2 and HBB gene defects. The pro-
band’s mother also presented blood parameters consistent
with iron-deficient anaemia. She referred mild hyper-
menorrhea but was negative for the most common malab-
sorption causes. She was treated with oral iron, with poor
results (haemoglobin 75 g/l vs. 91 g/l after 5 months oral
iron therapy).
In the Portuguese Family 2, a 9-year-old girl was diag-
nosed with microcytic anaemia, low serum iron and normal
ferritin (Fig 1B, C). After no response to oral iron therapy,
she started with i.v. iron, with no response (haemoglobin
increase 5 g/l, with no reticulocytosis). Ferritin increased sig-
nificantly (360 pmol/l) but iron remained low. Specific tests
excluded other causes of iron-deficiency anaemia, such as
malabsorption and bleeding, and the common alpha/beta
thalassemia mutations. Her mother had a non-symptomatic
mycrocitic and hypochromic anaemia (Fig 1C). Again, spe-
cific tests excluded secondary causes of iron deficient anae-
mia or thalassemia trait (including common alpha/beta
thalassemia mutations). The father had hyperferritinaemia,
probably due to heavy alcohol consumption. A microcytic
anaemia refractory to oral iron therapy was also documented
in a 6-year-old maternal cousin. Serum hepcidin-25 values
(A)
(C)
(B)
Fig 1. (A, B) IRIDA Family trees with single member genotypes. Arrows indicate probands. Subjects unavailable for the analysis are shown in
grey. (C) Haematological and biochemical parameters for the two families. Hb: haemoglobin; Hct: haematocrit; MCV: mean cell volume; MCH:
mean cell haemoglobin; MHC: mean haemoglobin concentration; TSAT: transferrin saturation; EPO: erythropoietin; (TSAT)/Hepcidin-25: Trans-
ferrin saturation/serum hepcidin-25 ratio. Reference values are reported on the right. Values outside normal ranges are indicated in bold. *A low
transferrin saturation (TSAT)/Hepcidin-25 ratio may be consistent with Iron Refractory Iron Deficiency Anaemia (IRIDA), (http://www.hepcidin-
analysis.com).
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and serum transferrin saturation/hepcidin-25 ratio, a marker
for IRIDA, showed values below the reference for both the
proband and her mother (Fig 1C).
After all family members provided informed consent,
DNA was extracted from peripheral blood. TMPRSS6 exons
and exon-intron boundaries were amplified and automati-
cally sequenced. HBA1/HBA2 and HBB molecular analysis
was performed with a reverse dot blot kit (Nuclear Laser
Medicine Strip Assay, Italy). The effect of mutations on
TMPRSS6 mRNA maturation was predicted utilizing the ALA-
MUT (Interactive Biosoftware, Rouen, France) and the Human
Splicing Finder (Desmet et al, 2009) software. For expression
analysis of mutated transcripts, total RNA was extracted from
peripheral blood mononuclear cells, reverse-transcribed and
amplified by qualitative or quantitative real time polymerase
chain reaction (PCR).
A previously reported mutation in exon 8 (1025 C>T,
S304L) (De Falco et al, 2010) was found in heterozygosity in
Family 1 proband (Fig S1), which was also present in her
father and brother (Fig 1A). On the other patient’s allele, a
9 bp deletion was identified in heterozygous form at the end
of intron 8 (IVS8-1433 D9) (Fig S1), which was inherited
from her mother (Fig 1A). In silico analysis predicted that
the deletion abolishes the constitutive splice site and favours
the use of a cryptic site 17 bp upstream (Fig 2A). As a con-
sequence of this, 8 bp are added to the coding sequence,
causing a frameshift and the creation of a premature stop
codon (Fig 2B). Real time PCR analysis revealed the presence
of two mRNA forms in the proband, one of which was
found at lower amounts compared to the other (Fig S2).
This is probably due to the faster degradation of the mutated
mRNA in comparison to the wild-type.
A heterozygous mutation at the end of intron 15
(c. 1869-21 C>G) was identified in the proband from Fam-
ily 2 (Fig S1), which was inherited from her mother
(Fig 1B). Two synonymous polymorphisms (rs11704654 and
rs2235321, corresponding to Pro32 and Tyr738 respectively),
previously associated with IRIDA (Delbini et al, 2010) were
also found, both of which were also present in the pro-
band’s father. In silico analysis of the effect of the c. 1869-
21 C>G mutation predicted the creation of a new splicing
site, approximately 50% stronger than the native site, local-
ized 21 bp downstream (Fig 2A). The mutated mRNA
would contain an extra 20 bp, causing a frameshift and the
creation of a premature stop codon. As a consequence, the
new protein would lack 96% of the serine protease domain
(Fig 2C). Analysis of mRNA expression using primers
amplifying the mutated locus showed the presence of two
mRNA forms differing by approximately 20 bp, while
amplification with primers specific for the mutation was
observed only for the proband and her mother (Fig S2).
The characterization of new mutations in the TMPRSS6
gene in two young patients with IRIDA further confirms
the allelic heterogeneity of this disorder. In Family 1, the
(A)
(B) (C)
Fig 2. (A) Prediction of creation of potential splicing sites in mutated TMPRSS6 sequences, using Human Splicing Finder. (B) Schematic repre-
sentation of the effects of IVS8-1433Δ9 and (C) c. 1869-21 C>G mutations on mRNA processing. Capital letters in the gene schematics indicate
transcribed nucleotides. Deleted/mutated nucleotides are in red, cryptic acceptor splice sites are marked by asterisks, dotted areas show the added
transcribed sequences.
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presence of the IVS8‐1433D9 variation at the heterozygous
state in the mother was associated with a consistent anaemia
that was resistant to oral iron therapy and not completely
explainable by secondary causes. In Family 2, the new
1869-21 C>G mutation is associated with two iron defi-
ciency-related polymorphisms both in the proband and her
symptomatic cousin. The two polymorphisms alone cannot
be accountable for the disease, as these are both present in
the proband’s asymptomatic father. Thus, it is apparent that
the development of IRIDA symptoms in Family 2 needs the
presence of the 1869-21 C>G mutation. Curiously, the pro-
band’s mother, who carries the 1869-21 C>G mutation, but
not the two polymorphisms, although asymptomatic, has a
picture of mild iron-deficient anaemia.
In conclusion, the data suggest that although heterozy-
gous TMPRSS6 mutations may not be able to induce a clear
IRIDA phenotype, some of them may increase the suscepti-
bility to iron deficiency.
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Fig S1. Electrophoretograms of the TMPRSS6 genomic
sequences spanning the mutations found in Family 1 (a) and
in Family 2 (b) patients. The DNA sequences of a wild type
subject (WT) and of the probands (P) are shown. Mutations
are indicated by asterisks.
Fig S2. (a) RT-PCR melting curves of Family 1 father (I-
1, upper panel) and proband (II-4, middle panel) TMPRSS6
transcripts. Abelson Tyrosine-kinase (ABL) cDNA amplifica-
tion, used as calibrator, is shown in the bottom panel. The
pink line represents the established threshold. (b) Effects of
the c. 1869-21C>G mutation on TMPRSS6 mRNA. Upper
panel: Alternative spliced cDNA created by the mutation
electrophoresed on agarose gel. cDNAs including the
mutated loci (1 and 2) or specific for the mutated sequence
(3) were obtained and amplified for the proband (P), mother
(M) and father (F) and electrophoresed. Two bands, with
molecular weights in agreement with the predicted WT (404
and 158 bp, respectively for amplicons 1 and 2) or mutant
(424 and 178 bp, respectively for amplicons 1 and 2) sizes
were observed for proband and mother, whereas only the
smaller band was observed for the father. A band corre-
sponding to the mutated sequence (140 bp) was only
observed in the proband and mother. L: 1Kb DNA Plus Lad-
der. Bottom panel: Map of the expected amplicons for WT
and mutated regions.
Please note: Wiley-Blackwell are not responsible for the
content or functionality of any supporting materials supplied
by the authors. Any queries (other than missing material)
should be directed to the corresponding author for the
article.
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Food allergy after cord blood transplantation in children
A significant number of factors play an important role in the
development of food allergy (FA), including early introduc-
tion of solid food, genetically determined bias toward a
T helper cell type 2 (Th2) environment, and polymorphisms
of Th2 cytokine and immunoglobulin E (IgE) receptor genes.
While most food allergies are IgE-mediated, a number of
non-IgE-mediated gastrointestinal FA affect mainly infants
and young children (Sicherer & Sampson, 2010). Allogeneic
haematopoietic stem cell transplantation (HSCT) is an opti-
mal treatment for haematological disease. Agosti et al (1988)
reported transfer of allergen-specific IgE-mediated hypersen-
sitivity with allogeneic bone marrow transplantation (BMT).
The passive transfer of B- and/or helper T-cell clones with
allergen-specific memory within the BM inoculum is a possi-
ble mechanism.
Here a chart review was performed to conduct a retro-
spective analysis of the development of FA among 14 chil-
dren (0·4–13 years) who survived for more than 1 year after
cord blood transplantation (CBT) between 1998 and 2011 at
our institute. The study protocol was approved by our insti-
tutional review board. Four patients were transplanted with
fully human leucocyte antigen (HLA)-matched unrelated CB
cells, and nine cases were from HLA-mismatched unrelated
donors after total body irradiation (6–12 Gy)-containing reg-
imen. Twelve patients received tacrolimus (FK506) and
methylprednisolone as graft-versus-host disease (GVHD)
prophylaxis. One patient received FK506 and short-term
methotrexate, and the remaining patient was given cyclospor-
ine (CsA) and short-term methotrexate. After engraftment,
the dose of methylprednisolone was tapered and discontin-
ued up to day 30 in the absence of acute GVHD. At 3–
6 months following CBT, five children developed urticaria,
angioedema, diarrhoea and vomiting, alone or in combina-
tion immediately after the ingestion of one or more foods
(soybean, milk, cow’s milk, egg, rice, etc., Table I). The five
patients had neither past history nor family history of allergic
disorders before CBT. Mean age at CBT was 1·6 ± 1·3 years
in five patients with the symptoms described above and
5·6 ± 4·5 years in nine patients without the symptoms
(P = 0·06). At the appearance of the symptom(s), four
patients had been treated with FK506 with or without
methylpredonisolone and the remaining patient with CsA
because of the development of acute GVHD. Their FK506
and CsA blood levels were 4·5–10·6 and 98–132 ng/ml,
respectively. Avoidance of the suspected food(s) resolved the
symptoms in all five patients. Taking these findings together,
we made the diagnosis of post-CBT FA. At the occurrence of
FA symptoms, total IgE levels were not high in all the
patients except for Patient 5. Total IgE levels reached the
maximum (higher than 3000 iu/ml) at 9 and 26 months
after the onset of FA, in Patients 1 and 2, respectively. Addi-
tionally, specific IgE tests revealed apparent positivity against
multiple foods. No increases in specific IgE were noted
during the clinical course in the other three patients. Patient
1 had specific IgE against caseins, alpha-lactalbumin, and
beta-lactoglobulin, at 50·9, 0·42 and 1·16 allergen units (au)/
ml, respectively. Skin prick tests were not performed. Repro-
ducibility of the allergic reaction was found‘ by allergen chal-
lenge in four patients. Colonic biopsy revealed chronic
inflammation with modestly increased eosinophil infiltration
in the lamina propria of terminal ileum and colon in
Patients 4 and 5. The characteristic findings of cord colitis
syndrome described by Herrera et al (2011) were not identi-
fied. Thus, post-CBT FA may result from both IgE-mediated
reaction to foods and non-IgE-mediated reaction associated
with food protein-induced enterocolitis syndrome (Boyce
et al, 2010). To our knowledge, this is the first report of
post-CBT FA. Patient 1 has been allowed to return to a full
diet with the exception of soybeans. As the remaining
patients showed no allergic symptoms following the ingestion
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